Welcome to Penn State Hershey Cancer Institute
Intellect and discovery characterize growth at the Penn State Hershey Cancer Institute. We continue to emphasize our state-of-the-art interdisciplinary patient care, in which medical, surgical and radiation oncologists jointly determine the best therapeutic course for each patient. We also focus our attention on becoming designated by the National Cancer Institute (NCI). Among other strengths, the Cancer Institute's emphasis on rural, underserved populations is a focus of the CCSG application. Many of these efforts are conducted through the Appalachian Cancer Network by volunteers throughout Pennsylvania who provide education and screening services, as well as behavioral interventions, to reduce cancer risk. Our free-standing facility, which opened June 2009, was designed to reinforce our concept of a community of individuals devoted to providing comprehensive cancer care and finding a cure for cancer.
The Cancer Institute's three scientific programs:
The scientists in the Cancer Control and Population Health and the Mechanisms of Carcinogenesis and Chemoprevention Programs continue collaborative work on two major grants examining the role of tobacco in leading to cancer. In the Experimental Therapeutics Program, our scientists have been awarded several grants from NCI in the area of nanotechnology. These projects, developed with leading researchers at University Park, are aimed at delivering new cancer treatments to individual cancer cells. Through our network of local hospitals throughout central and northeastern Pennsylvania, the Penn State Hershey Cancer Institute brings research to patients in a growing number of communities. Click here for a list of our partners and affiliates.
We continue to expand our research programs. PSHCI now has 143 investigators from 25 academic departments in six colleges located at the Hershey and University Park campuses. Over the past five years, our NCI funding has increased by 16% with a 22% increase in the past 3 years. This is quite impressive given the funding crisis at the NIH. We are making similar strides in the area of clinical trials. In the past year, 18% of our new cancer patients were enrolled on a therapeutic or prevention trial.